(Report ID: 150063) Drug interactions analysis of:
Medroxyprogesterone Acetate, Premarin, Prempro, ProveraMany drug interactions and side effects can not be detected until the drugs have been used by millions of people, and for a long time. Large, long-term drug safety studies are ideal to discover these real-world drug outcomes. For the first time, eHealthMe enables health professionals and patients to conduct these studies for their drugs. Click here to check your drugs now, in a whole new way. As of Nov, 20, 2008, eHealthMe analyzes 10,180,580 drug interactions and side effects of 21,667 FDA-approved drugs from 1977 to the present. Results on Nov, 20, 2008: 6,960 relevant incidents
Note:
- The incidents can not include all actual occurrences
- Data of 2008 is not complete
DISCLAIMER: All adverse drug reaction material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only, and has not been supported by scientific studies or clinical trials unless otherwise stated. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk. Basic information:
| Report ID | Date of submission | Patient age | Patient gender |
| 150063 | Jun, 28, 2006 | Not specified | Female |
List of drugs the patient takes:
| Drug |
Medroxyprogesterone Acetate |
Premarin |
Prempro |
Provera |
| Name |
Breast Cancer Female |
Results from eHealthMe: 6,960 relevent incidents1) Comparison with the patient's adverse outcomes:
| Name | Count (% of total reports) |
Breast Cancer Female | 2,053 (29.50%) |
Death: 0
Cancer: 1,004 (95.98% of total reports)
| Name | Count (% of total reports) |
1 | Breast Cancer | 624 (59.66%) |
2 | Breast Cancer Metastatic | 263 (25.14%) |
3 | Deep Vein Thrombosis | 42 (4.02%) |
4 | Breast Cancer Female | 36 (3.44%) |
5 | Pulmonary Embolism | 28 (2.68%) |
6 | Cerebrovascular Accident | 22 (2.10%) |
7 | Ovarian Cancer Metastatic | 20 (1.91%) |
8 | Breast Cancer In Situ | 18 (1.72%) |
9 | Breast Cancer Recurrent | 17 (1.63%) |
10 | Myocardial Infarction | 14 (1.34%) |
3) Top co-used drugs drugs reported for the past 12 months:
| Name | Count |
1 | Cycrin | 197 |
2 | Estrace | 71 |
3 | Conjugated Estrogens | 34 |
4 | Estraderm | 33 |
5 | Estratab | 20 |
6 | Prometrium | 19 |
7 | Estradiol | 19 |
8 | Femhrt | 18 |
9 | Activella | 16 |
10 | Climara | 14 |
Death: 3 (0.04% of total reports)
Cancer: 6,929 (99.55% of total reports)
| Name | Count (% of total reports) |
1 | Breast Cancer | 3,510 (50.43%) |
2 | Breast Cancer Female | 2,053 (29.50%) |
3 | Breast Cancer Metastatic | 714 (10.26%) |
4 | Oestrogen Receptor Assay Positive | 419 (6.02%) |
5 | Progesterone Receptor Assay Positive | 364 (5.23%) |
6 | Breast Cancer In Situ | 241 (3.46%) |
7 | Ovarian Cancer | 162 (2.33%) |
8 | Deep Vein Thrombosis | 140 (2.01%) |
9 | Cerebrovascular Accident | 130 (1.87%) |
10 | Metastases To Lymph Nodes | 128 (1.84%) |
| Name | Count |
1 | Cycrin | 1,176 |
2 | Estrace | 617 |
3 | Estraderm | 312 |
4 | Estradiol | 269 |
5 | Activella | 221 |
6 | Femhrt | 202 |
7 | Estratab | 193 |
8 | Climara | 188 |
9 | Vivelle | 133 |
10 | Prometrium | 123 |
Want to have a risk analysis report like this for your drugs? Click here. ADVERTISEMENT
----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- Recent drug risk analysis reports:
|
|
|
 |
|
How to use the report?
Bring a copy of this report to a doctor's appointment to ensure drug risks are fully discussed and understood, in the process of risk and benefit assessment.
|
 |
|
ADVERTISEMENT
|
|
